Video

Educated Patient® Kidney Cancer Summit: October 24, 2021

Author(s):

CURE Media Group

View the full CURE Educated Patient Kidney Cancer Summit on demand.

Related Videos
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Image of woman with black hair.
Image of woman with blonde hair.
Related Content
Image of solid tumor makeup.
January 20th 2025

The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors

Ryan Scott
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
An image of lung cancer.
January 8th 2025

Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors

Ryan Scott
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Image of kidney cancer.
January 8th 2025

BLA Has Been Submitted For Kidney Cancer Imaging PET Product Zircaix

Ryan Scott
A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.